Research Article

Topical Formulation of Noscapine, a Benzylisoquinoline Alkaloid, Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesions

Fahimeh Nourbakhsh,¹ Seyed Hadi Mousavi,¹ Pouria Rahmanian-Devin,² Vafa Baradaran Rahimi,³ Hassan Rakhshandeh ^(D),² and Vahid Reza Askari ^(D),^{2,4,5,6}

¹Medical Toxicology Research Centre, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran ²Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran

³Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

⁴Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁵Department of Pharmaceutical Sciences in Persian Medicine, School of Persian and Complementary Medicine,

Mashhad University of Medical Sciences, Mashhad, Iran

⁶Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Vahid Reza Askari; askariv@mums.ac.ir

Received 6 January 2022; Revised 17 March 2022; Accepted 5 April 2022; Published 22 April 2022

Academic Editor: Xiang Liu

Copyright © 2022 Fahimeh Nourbakhsh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Psoriasis is considered an autoimmune inflammatory disease. The disease is spread and diagnosed by the infiltration of inflammatory mediators and cells into the epidermis. Recent theoretical developments have focused on the effectiveness of noscapine (NOS) as a potential alkaloid for being used as a valuable treatment for different diseases. In the present study, psoriasislike dermatitis was induced on the right ear pinna surface of male *Balb/c* mice by topical application of imiquimod (IMQ) for ten consecutive days, which was treated with noscapine (0.3, 1, 3, and 10% w/v) or clobetasol (0.05% w/v) as a positive control. The levels of ear length, thickness, severity of skin inflammation, psoriatic itch, psoriasis area severity index (PASI) score, and body weight were measured daily. On the 10th day of study, each ear was investigated for inflammation, fibrosis, proliferation, and apoptosis using histopathological (H&E and Masson's trichrome staining) and immunohistochemistry (Ki67 and p53 staining) assays. Furthermore, the levels of inflammatory biomarkers were characterized by an enzyme-linked immunosorbent assay (ELISA). The results confirmed IMQ-induced psoriasis for five consecutive days. In contrast, noscapine significantly reduced the ear length, thickness, severity of skin inflammation, psoriatic itch and body weight, tumor necrosis factor- α (TNF- α), transforming growth factor- β (TGF- β), interferon-gamma (IFN- γ), interleukin 6 (IL-6), IL-17, and IL-23p19 in a concentrationdependent manner (P < 0.001-0.05 for all cases). Overall, topical noscapine significantly ameliorated both the macroscopical and microscopical features of psoriasis. However, further clinical investigations are required to translate the effects to clinics.

1. Introduction

Inflammation is defined by a series of events beginning with an induction phase, progressing to a maximum of inflammation, and then ending with a resolution phase [1-3]. Acute inflammation allows for rapid and complete immune activation, which is necessary for successful innate immunity defense [1-4]. It starts with detecting exogenous and endogenous surface receptors caused by mechanically, chemically, or biologically induced tissue damage, followed by the recruitment of effector cells, which also orchestrates an inflammatory reaction defined by the release of lipid and protein-based mediators of inflammation [5].

Psoriasis is an autoimmune and chronic inflammatory disease in which keratinocytes are impressed with significant proliferation and abnormal differentiation [6]. The infiltration of inflammatory cells and related inflammatory mediators characterizes the disease into the epidermis and causes severe changes in the vascular system of the dermis [7]. Patients typically describe scaling of the body surface, itching, erythema, burning, and bleeding as symptoms. The prevalence of this disease globally is reported by 2-3% (more than 125 million people in the world), which is probably the most common autoimmune skin disease [8]. Both genetics and environmental factors are contributing to the disease [9]. In this regard, family history has been reported in approximately 30% of psoriatic patients. These patients have also observed polymorphisms of genes that regulate angiogenesis and inflammation [10, 11]. The entry of various immune cells and the production of inflammatory and proinflammatory cytokines in the epidermis intensify the inflammation in this area and develop psoriasis lesions [12]. Studies have shown that CD4⁺ and CD8⁺ T-cells play a fundamental role in the pathogenesis of psoriasis, initiating inflammation, and keeping inflammation in place.

On the other hand, the critical role of T-cells in psoriasis has been proven [13]. Although the exact pathogenesis of this disease is not yet fully understood, there is growing evidence that interleukin (IL)-23/IL-17A has a significant impact on the pathogenesis of the disease. In addition, several studies have demonstrated that the primary source of IL-17A production in the skin is $\gamma\delta$ -T cells producing IL-17A by stimulating IL-23 [14]. Many inflammatory cytokines, including IL-23, IL-17A, IL-20, IL-22, IL1-β, IL-6, and TNF-**\alpha** (tumor necrosis factor- α), act as a complex in the disease development [14]. Imiquimod (IMQ), a ligand for toll-like receptors (TLRs)-7/8 and a potent activator of the immune system, is used to treat genital and anal warts (caused by human papillomaviruses, HPV) selected as a psoriasis experimental design [15, 16]. In this regard, experimental data have shown that IMQ causes human-like dermatitis similar to psoriasis in animal studies. It was demonstrated that IMQ used in the treatment of active warts and keratosis could activate dendritic cells, plasma dendritic cells (PDCs), natural killer (NK) cells, and T lymphocytes to produce inflammation by interferon (IFN)-y and IL-17/IL-23 secretions [14]. The experimental validation of this model might pave the way for novel treatment approaches that target upstream processes in psoriasis etiology [17]. Due to the use of this drug on the skin of mice, it causes the rapid entry of PDCs into the site. In fact, this drug's antiviral and antitumor activity is mainly mediated by activation of TLR-7 and TLR-8 (expressed by monocytes, macrophages, and PDCs) [18]. Although low doses of methotrexate and other suggested treatments are used weekly for psoriasis, numerous adverse effects have been reported for these medications, including hematological and gastrointestinal disorders such as abdominal discomfort, stomach pain, nausea and vomiting, and drowsiness [19, 20]. Therefore, the use and findings of medicines that control the severity of psoriasis with the least amount of adverse effects are a priority in the treatment and alleviation of psoriasis.

Noscapine is a benzyl alkaloid isoquinoline found in dark poppy plants with no opioid-like adverse effects [21–23]. However, it has been reported to inhibit cell proliferation in a wide range of cancer cells, even in many drugresistant species [23–25]. Furthermore, noscapine has been

demonstrated to be safe and to have no toxic effects on humoral or cell-mediated immunity. Along with its antitussive and antistroke effects, these findings generated an interest in establishing other roles of noscapine. The pharmacology of noscapine, as well as its effects on cellular signaling pathways, the mitotic spindle, and centrosome clustering, as well as its use as an antimalarial and cough suppressant, and its exceptional potential as a treatment for polycystic ovarian syndrome, strokes, and a variety of malignancies, are all detailed [22, 23]. Moreover, it has been indicated that noscapine could reduce the levels of inflammatory cytokines, such as IL-2, TNF- α , and IL-6, in different in vitro and in vivo models [22-25]. Therefore, in this study, we tried to evaluate the effectiveness of topical administration of noscapine in the animal model of IMQinduced psoriasis with several macroscopic (such as ear length, thickness, severity of skin inflammation, psoriatic itch, psoriasis area severity index (PASI) score, and body weight), histopathologic (Hematoxylin and eosin, H&E, for inflammation and inflammatory cells infiltration levels, and Masson's trichrome for the fibrosis level), immunohistochemistry (Ki-67 as a marker of cell proliferation and p53 as a marker of cell apoptosis), and molecular (cytokines production) methods.

2. Materials and Methods

2.1. Chemicals and Reagents. Noscapine powder (purity 99.5%) was of analytical grade and bought from FaranShimi® Company, Hamedan, Iran. Cold cream was of commercial grade and obtained from Farabi® Company, Tehran, Iran. Unless otherwise noted, all chemicals and reagents were acquired from Sigma-Aldrich (St. Louis, MO, USA). Furthermore, 5% w/w imiquimod propionate cream patches was prepared from Aldara, MEDA, Sweden. The cytokine chemical and reagent characterizations were acquired from the eBioscience® company (St. Louis, MO, USA). Enzyme-linked immunosorbent assay (ELISA) kits were obtained for TNF- α , TGF- β , IFN- γ , IL-10, IL-6, IL-17A, and IL-23p19. Immunohistochemical examination was performed using the antibodies against Ki-67 protein (ZYTOMED) and p53 protein (GenomeMe) based on the kit protocols.

2.2. Preparation of Noscapine Cream. To prepare noscapine cream in the lowest dose (0.3 %w/w), 300 mg of noscapine was levigated in 2 mL of glycerin and then mixed with cold cream to have the final mixture of 100 g. Similarly, further doses of 1%, 3%, and 10% w/w of noscapine cream were prepared with the same method and different levels of noscapine. The final cream had good stability and illustration and was in a smooth consistency.

2.3. Animal Husbandry and Ethical Statements. Forty-two male inbred Balb/c mice (weighing 25.2 ± 4.6 g) were obtained from the Faculty of Medicine Animal Laboratory, Mashhad University of Medical Sciences, Mashhad, Iran, and then randomly divided into six groups for this research

Evidence-Based Complementary and Alternative Medicine

(n=7/group). Animals were housed in cages at $22 \pm 1^{\circ}$ C along with temperature conditions of 19-26°C, relative humidity of 70-70%, the light intensity of 300 lux, and exposure of 12 light/dark cycles. All animals had free access to food and tap water. Three or four mice were housed in each cage at better condition, which measured $206 \times 365 \times 140$ mm. Moreover, the mice were acclimatized for one week before starting the study. In fact, all animal procedures were carried out in compliance with the National Institutes of Health's Guide for the Use and Care of Laboratory Animals guidelines of institutional guidelines. Moreover, the Mashhad University of Medical Sciences Ethical Committee approved all procedures involving animals based on the policies of animal experiments and care (Ethical approval code: 990587, Approval date: 2020–09–07, Approval ID: IR.MUMS.MEDICAL.REC.1399.463).

2.4. Psoriasis Induction and Experimental Protocol. To induce psoriasis from the first day, a certain amount of 5% w/w IMQ cream (10 mg/cm^2 of skin) was used on the right ear pinna of mice in each group. Daily photographs were taken to record changes in skin lesions and were scored based on PASI scores, inflammation, thickness, and redness of mice's right ear pinna. Doses of medication and treatment were used for ten days. *Balb/c* mice were grouped as follows.

Group I: sham group, received a daily topical cold cream application as the vehicle on the right ear pinna. *Group II*: negative control group, received a daily topical dosage of 5% IMQ cream (10 mg/cm² of skin) on the right ear pinna (left ear pinna was untreated as the internal control), and after 30 min received a daily topical cold cream, as the vehicle, on the right ear pinna.

Group III: positive group, received a daily topical dosage of 5% IMQ cream on the right ear pinna (left ear pinna was untreated as the internal control), and after 30 min received a daily topical clobetasol cream (0.05 % w/w) on the right ear pinna.

Group IV: NOS 0.3% w/w, received a daily topical dosage of 5% IMQ cream on the right ear pinna (left ear pinna was untreated as the internal control), and after 30 min received a daily topical 0.3% w/w noscapine cream on the right ear pinna.

Group V: NOS 1% w/w, received a daily topical dosage of 5% IMQ cream on the right ear pinna (left ear pinna was untreated as the internal control), and after 30 min received a daily topical 1% w/w noscapine cream on the right ear pinna.

Group VI: NOS 3% w/w, received a daily topical dosage of 5% IMQ cream on the right ear pinna (left ear pinna was untreated as the internal control), and after 30 min received a daily topical 3% w/w noscapine cream on the right ear pinna.

Group VII: NOS 10% w/w, received a daily topical dosage of 5% IMQ cream on the right ear pinna (left ear pinna was untreated as internal control), and after

30 min received a daily topical 10% w/w noscapine cream on the right ear pinna.

All doses were calculated based on the preliminary study with a three-fold increment in dose. An illustration of the experimental procedures is shown in Table 1.

2.5. Scoring Severity of Skin Inflammation. The levels of erythema, thickness, and scaling on the afflicted ear pinna surface were used to calculate PASI (Psoriasis Area and Severity Index) scores. On a four-point scale, PASI was calculated for each mice (0 = none; 1 = slight; 2 = moderate; 3 = marked; 4 = extremely marked). The total score was measured by the combined scores (scaling, erythema, and thickness). Ear thickness and ear length were measured in both ears every day with digital calipers (BEC, China). These factors are the criteria for the amount of epidermal growth and inflammation was measured by the rise in ear thickness and inflammation [26].

2.6. Behavioural Tests of IMQ-Induced Psoriatic Itch. Mice were acclimated to a plexiglass recording arena twice for 60 minutes each time before being tested. In addition, mice were recorded from above for 60 minutes two hours following each topical administration. A scratch bout was characterized as one or faster back-and-forth hind paw motions aimed at and touching the treated region, culminating in toe licking or biting or planting of the hind paw on the floor. Grooming motions and posterior paw movement directed away from the treatment region (e.g., ear scratching) were not counted [27].

2.7. Evaluating the Mice's Spleen, Ear, and Body Weight. At the end of the study, animals were sacrificed, and the tissues were dissected and kept at -70° C. In this way, the spleen and ear of each mouse were isolated, weighed and then photographed, and stored in a freezer with -70° C or 10% v/v formalin for further examinations. In addition, the spleen and ear index were calculated by dividing the weight of the spleen or ear of each mouse by the bodyweight of the mouse on the last day.

2.8. Histopathological Examination. Right ear pinnas were selected as a tissue sample and then were fixed in 10% v/v neutral-buffered formalin. Samples were placed separately in 10% v/v formalin in a Falcon-tube and delivered to the pathology laboratory. The samples were immersed in parafin blocks and finally cut to a thickness of 4μ m. Hematoxylin and eosin (H&E, evaluating inflammation and inflammatory cells infiltration levels) and Masson's trichrome (evaluating fibrosis level) stainings were considered for each sample and photographed with a digital camera microscope [28–30]. The ear was considered for H&E and Masson's trichrome stainings.

Moreover, the spleen and cervical spinal cord (C3–C4) was also selected for H&E staining investigation, including inflammation and cellular infiltrations. The stained tissues were photographed with a digital camera microscope

Protocol	Groups		Treatment day
(<i>n</i> = 7/each group) Psoriatic lesion and Noscapine therapy	ShamDaily topical cold cream (10 mg/cm² of skin)Control negativeDaily topical dosage of 5% IMQ cream (10 mg/cm² of skin)Daily topical dosage of 5% IMQ + Daily topical clobetasol		
	Control positive Treatment	cream (0.05 %w/w) Daily topical dosage of 5% IMQ + daily topical 0.3% w/w noscapine cream Daily topical dosage of 5% IMQ + daily topical 1% w/w noscapine cream Daily topical dosage of 5% IMQ + daily topical 3% w/w noscapine cream Daily topical dosage of 5% IMQ + daily topical 10% w/w	Day 1–10
		1	

TABLE 1: Illustration of the experimental procedures.

(Nikon, Eclipse E200). The pathologic changes in the ear pinna of various groups were included: acanthosis, parakeratosis, and thickening of the subepidermal layer. These factors were evaluated semi-quantitatively on a scale of 0-10 (0 = No clinical signs or change, 1 = Partial inflammation,2 = Slight inflammation and tissue damage in mice, 3 = Increased levels of inflammation and tissue destruction of the right ear pinna, spinal cord and increased spleen leukocytes, 4 = Low increase in epidermis thickness and inflammation, 5 = Moderate inflammation, ear pinna thickness, and low parakeratosis 6 = Moderate inflammation, moderate ear pinna thickness, epidermal parakeratosis 7 = Increasing inflammation, ear pinna thickness, epidermal parakeratosis, and a low score of hyperplasia of the epidermis 8 = Ear pinna thickness and inflammation, marked areas of necrosis with vacuolization of cells, epidermal parakeratosis, 9 = Ear pinna thickness and inflammation, parakeratosis of the epidermal layer, 10 = Maximum inflammation, increased inflammatory infiltration and hyperplasia of the epidermis and acanthosis) [26, 31].

2.9. Immunohistochemistry Examination. Immunohistochemistry (IHC) [32] is the method for detection of a specific antigen in a tissue, cell, or particular phase of a cell life cycle based on antigen-antibody detection using light microscopy [33]. In the present study, we performed IHC for detecting the Ki-67 as a marker of cell proliferation and the p53 as a marker of cell apoptosis in the right ear pinnas based on their kits' manual [32, 33]. The basic steps of the IHC-P protocol are as follows: (1) Fixing and embedding the tissue, (2) cutting and mounting the section, (3) deparaffinizing and rehydrating the section, (4) antigen retrieval, (5) immunohistochemical staining, (6) counterstaining (if desired), (7) dehydrating and stabilizing with mounting medium, and (8) viewing the staining under the microscope. These factors were semiquantitatively scaled of 0-10 (0 = no change from untreated ears to 10 = maximum).

2.10. Total Protein Measurement Method. The Bradford protein assay was carried out to quantify the total protein concentration in each sample [2, 3, 34, 35]. In this regard, first, the Coomassie brilliant blue G-250 dye (10 mg) was dissolved in 50 ml ethanol 96%. Then, phosphoric acid 85% v/v (10 ml) was added, and the volume of the solution was increased to 100 ml. Thereafter, bovine serum albumin (4 mg/ml) solution was prepared as a standard curve. Then, after sample pouring (20 μ l), a Bradford reagent (200 μ l) was added to the 96-well microplate. Finally, the light absorption was read at 595 nm with a microplate reader after 5 minutes [2, 3, 28, 35].

2.11. Cytokine Assessments. The right ear pinnas of the mice were excised and kept at -70° C to evaluate cytokine measurement in skin tissue. The skins were homogenized at 4°C in tissue protein lysis buffer. In the following, the supernatants were selected for measuring the concentration of cytokines such as TNF- α , TGF- β , IFN- γ , IL-10, IL-6, IL-17A, and IL-23p19. ELISA was performed under the manufacturer's instructions based on the kits' protocols [2, 3, 28, 35].

2.12. Statistical Analysis. Data were analyzed using GraphPad Prism ® software version 8 (GraphPad Software, San Diego, CA) and presented based on the natures of parametric or non-parametric as means \pm SD or median \pm range (for the pathological score, including acanthosis, parakeratosis, thickening of subepidermal, histology score), respectively. The normality test was done for parametric data, based on the Kolmogorov-Smirnov and Bartlett's tests that assess the homogeneity of variances. Thereafter, comparisons between groups were carried out using a two-way analysis of variance (ANOVA) followed by a Sidak's multiple comparisons post hoc test. Repeated measures two-way ANOVA was done with the following Dunnett-T₃ multiple comparisons post hoc test for clinical scores. Non-parametric data were analyzed using the Kruskal-Wallis and Dunn's post-hoc multiple comparisons tests. The Brown-Forsythe test was also used if the SD was not equal and the statistical test in the equality of group variances based on performing an analysis of variance. Noteworthy, when *P* values (*P*) \leq 0.05, 0.01, and 0.001 were considered statistically significant [2, 3, 28, 35]. The data and statistical analysis complied with the recommendations on experimental design, analysis and data sharing, and presentation in preclinical pharmacology [36–38]. A summary of the statistical analysis is shown in Table 2.

TABLE 2: Summarized protocols of the present study.

ANOVAs table	Time F (DFn, DFd)	Number of columns (intervention)	Number of rows (time)	Time×intervention	ANOVAs test
Thickness	F (10, 60) = 147.7 P < 0.0001, N = 11	F (6, 42) = 471.7	307.4	F (60, 420) = 70.32	Two way ANOVA Dunnet
Erythema	F (10, 60) = 352.2 P < 0.0001, N = 11	F (6, 36) = 177.4	11	F (60, 360) = 25.42	Two way ANOVA Sidak
Scales	F(10, 60) = 409.3 P < 0.0001, N = 11	<i>F</i> (6, 36) = 124.4	11	F (60, 360) = 19.18	Two way ANOVA Sidak
Total score	F(10, 60) = 922.8 P < 0.0001, N = 11	F(6, 36) = 827.4	11	F (60, 360) = 72.62	Two way ANOVA Sidak
Ear length	F(10, 60) = 467.5 P < 0.0001, N = 11	<i>F</i> (6, 36) = 363.5	11	F (60, 360) = 53.04	Two way ANOVA Dunnet
Scratch bouts	F (10, 420) = 509.3 P < 0.0001, N = 11	F(6, 36) = 230.3	11	F (60, 360) = 31.27	Two way ANOVA Dunnet
Body weight	F (2.970, 17.82) = 15.12 P < 0.0001	7	7	F (6, 36) = 3.490	One-way ANOVA Dunnet
Spleen weight	F(6, 42) = 16.19 P < 0.0001	1	7	_	One-way ANOVA Dunnet
Ear index	F(6, 42) = 10.62 P < 0.0001	1	7	_	One-way ANOVA Dunnet
Spleen index	F(6, 42) = 21.30 P < 0.0001	1	7	_	One-way ANOVA Dunnet
TNF-0	F (6, 18) = 53.55 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
IL-10	F(6, 15) = 45.19 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
TGF- β	F(6, 22) = 49.82 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
IL-6	F(6, 15) = 31.8 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
INF-y	F(6, 10) = 57.52 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
INF-y/IL-10	F(6, 5) = 31.18 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
IL-17A	F (6, 14) = 52.85 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3
IL-23p19	F (6, 23) = 54.29 P < 0.0001	7	35	_	Brown Forsythe test Dunnet T3

3. Results

3.1. Effects of Noscapine on the Ear Thickness, Erythema, Scales, and Ear Length. The right ear pinna of the mice showed symptoms of erythema, scaling, and thickening a couple of days after commencing IMQ administration (Figure 1). In the IMQ group (II), the severity of psoriasis-like symptoms steadily increased until day ten compared to the sham group (Figures 1 and 2).

Our results showed that the IMQ 5% application significantly increased the ear thickness compared to the sham group (P < 0.001, Figure 2(a)). In contrast, all concentrations of NOS (0.3, 1, 3, and 10% w/w) significantly and concentration-dependently reduced the level of the ear thickness compared to the IMQ-treated alone group (P < 0.001 for all cases). Furthermore, the trend of thickness reduction in the treated groups was observed from day seven at 0.3, 1, and 3% w/w of noscapine concentrations (P < 0.001 for all cases, Figure 2(a)) and from day six in NOS 10% w/w (P < 0.001, Figure 2(a)).






FIGURE 1: Severity of psoriasis-like symptoms in all groups for ten days was showing (a) sham group, (b) negative control group, (c) positive group, (d) sample group received IMQ plus 0.3% w/w NOS, (e) sample group received IMQ plus 1% w/w NOS, (f) sample group received IMQ plus 3% w/w NOS, and (g) sample group received IMQ plus 10% w/w NOS.








FIGURE 2: Phenotypical observations of ear pinna in treated mice groups. The symptoms of the thickness (a), erythema (b), scaling (c), the total score (d), and ear length (e) after commencing IMQ administration right ear pinna of the mice. The results are expressed as the mean \pm SD (n = 7 in each group). The results indicate significant changes in the sham and negative control group (***P < 0.001).

The results also showed an upward trend in inflammation and redness in all groups, up to day five of psoriasis induction. This study shows that all concentrations of NOS had a reducing effect on the amount of erythema compared to the IMQ-treated alone group (P < 0.001 for all cases, Figure 2(b)).

Scales (0–4) indicated the focal formation of inflamed and prominent plaques in different groups due to the overgrowth of skin epithelial cells. Scoring ranges are from zero to four based on each mouse's erythema, scaling, and thickening. Our results indicated that the application of different concentrations of NOS (0.3, 1, 3, and 10% w/w) significantly reduced the scale range from day eight compared to the control group (P < 0.001 for all cases, Figure 2(c)). However, NOS 3% w/w (2.429 ± 0.202, P < 0.001, Figure 2(c)) and NOS 10% w/w (2.143 ± 0.143, P < 0.001, Figure 2(c)) had a significant reduction effect on scales on the treatment groups from day seven (Figure 2(c)).

In addition, our findings also demonstrated that the total score in the control group received IMQ was significantly increased compared to the sham group (P < 0.001, Figure 2(d)). On the contrary, the application of different concentrations of NOS (0.3, 1, 3, and 10% w/w) and also Clo significantly diminished the total score from day eight compared to the control group (P < 0.001 for all cases, Figure 2(d)).


The results showed a significant increase in ear length during the use of IMQ compared to the sham group (P < 0.001, Figure 2(e)). In contrast, the application of

different concentrations of NOS (0.3, 1, 3, and 10% w/w) significantly attenuated the ear length from day eight compared to the control group (P < 0.001 for all cases, Figure 2(e)).


3.2. Effect of Noscapine on the Spleen and Body Weight. The results showed that IMQ 5% w/w on the ear led to a significant increase in the body weight compared to the sham group (P < 0.001, Figure 3(a)). However, different concentrations of NOS (1, 3, and 10% w/w) meaningfully and concentration-dependently reduced the elevated body weight compared to the control group (P < 0.001 to 0.05 for all cases, Figure 3(a)).

The application of IMQ 5% w/w on the ear resulted in a significant elevation in the spleen weight compared to the sham group (P < 0.001, Figure 3(b)). The use of each Clo (P < 0.05), NOS 1% w/w (P < 0.01), NOS 1% w/w (P < 0.001), NOS 3% w/w (P < 0.001), or NOS 10% w/w (P < 0.001) notably reduced the elevated spleen weight compared to the control group (Figure 3(b)).


Ear (Figure 3(c)) and spleen (Figure 3(d)) indices were calculated by dividing the net weight of each respected organ by the body weight. As a result, both ear (P < 0.001, Figure 3(c)) and spleen (P < 0.001, Figure 3(d)) indices were increased in the IMQ control group compared to the sham group. Experimentally, using each Clo or NOS (0.3, 1, 3, and 10% w/w) notably reduced the elevated ear (P < 0.001–0.01



(e) FIGURE 3: Continued.



IMQ+0.3%NOS



IMQ+10%NOS

(f)

FIGURE 3: Investigation of mice in terms of body weight (a), the weight of the spleen (b), ear index (dividing weight of the ear to the bodyweight) (c), the spleen index (dividing weight of the spleen to the bodyweight) (d), representative photos of the spleen (e), and pathological investigation of the spleen (f), respectively showed in Figures 3(a)-3(f). The results are expressed as the mean \pm SD (n=7 in each group). The results indicate significant changes compared to the negative control group (***P < 0.001, **P < 0.01 and *P < 0.05).

for all cases, Figure 3(c)) and spleen (P < 0.001 for all cases, Figure 3(d)) indices compared to the control group.

Additionally, Figure 3(e) represents the spleen length of each group, including A: negative control group, B: positive group, C: sample group received IMQ plus 0.3% w/w NOS, D: sample group received IMQ plus 1% w/w NOS, E: sample group received IMQ plus 3% w/w NOS, F: sample group received IMQ plus 10% w/w NOS. Moreover, Figure 3(f) shows the spleen's normal white pulp and abnormal red pulp in various groups.

3.3. Effect of Noscapine on the Scratching Behavior. The spontaneous scratch bouts were continuously greater in IMQ-treated mice than in control animals and steadily increased with time compared to the sham group (P < 0.001, Figure 4(a)). The rate of pruritus in the groups receiving IMQ increased sharply, while this rate increased significantly on days two to five and remained at its maximum until day five of psoriasis induction (Figure 4(a)). Reduction of pruritus was observed considerably in treated mice from day seven at doses of 1% w/w (255.7 ± 5.2), 3% w/w (248.5 ± 4.5), and 10% w/w NOS (196.2 ± 29.2) (P < 0.001 for all cases, Figure 4(a)). H&E staining of spinal cord sections revealed marked areas of necrosis with vacuolization of cells (Figure 4(b)).

3.4. Effect of Noscapine on the Concentration of the Cytokines. ELISA assays were used to assess inflammatory cytokines, essentials for inflammation in ear tissues of normal, IMQ-received, and NOS treated groups. In-ear skin samples from IMQ-received mice, levels of TNF- α -mediated cytokines, notably TGF- β , IL-6, IFN- γ , IL-17, and IL-23p19, were substantially increased compared to the sham group (P < 0.001 for all cases, Figures 5(a)–5(h)). In contrast, different concentrations of NOS (1, 3, and 10% w/w) significantly and concentration-dependently decreased in TNF- α , TGF- β , IFN- γ , IL-6, IFN- γ /IL-10, IL-17A, and IL-23p19 and also increased in the IL-10 expression in comparison to the control group (P < 0.001-0.05 for all cases, Figures 5(a)–5(h)).

3.5. Effect of Noscapine on the Histopathological Examination. H&E and Masson's trichrome staining (Figures 6(a) and 6(b)) of tissues were stained for each sample and photographed with a digital camera microscope (Nikon, Eclipse E200). Stained slices of IMQ-treated right ear pinnas were determined to match phenotypic findings and PASI score values. The pathologic changes in the ear pinna of various groups were acanthosis (Figure 6(c)), parakeratosis (Figure 6(d)) and thickening of the subepidermal layer (Figure 6(e)). These factors were evaluated semiquantitatively on a scale of 0–10 (0 = no change from untreated ears; 10 = maximum).

The IMQ-treated mice's right ear pinna sections revealed substantially enhanced acanthosis (P < 0.001, Figure 6(c)), parakeratosis, (P < 0.001, Figure 6(d)) and thickening of the subepidermal layer (P < 0.001, Figure 6(e)) in comparison to the control group (Figures 6(a) and 6(b)). The results also demonstrated that applying NOS (0.3, 1, 3, and 10% w/w), or Clo

significantly reduced acanthosis (P < 0.001-0.01 for all cases, Figure 6(c)), parakeratosis (P < 0.001-0.01 for all cases, Figure 6(d)), and thickening of the subepidermal layer (P < 0.001for all cases, Figure 6(e)) in comparison to the control group.

3.6. Effect of Noscapine on the Immunohistochemical Examination. Immunohistochemistry (IHC) staining was performed to detect p53 as a marker of cell apoptosis (Figure 7(a)) and Ki-67 as a cell proliferation marker (Figure 7(b)) based on the kit protocols by light microscopy. Positive p53 was presented in the subepidermal layer viewed by the brown nuclei of epidermal cells. Furthermore, positive Ki-67 was shown in the epidermis and considered by the brown nuclei of epidermal cells. Additionally, Figure 7(c) also presented a histopathological score of examined tissues semiquantitatively on a scale of 0-10 (0 = no change from untreated ears; 10 = maximum change in treated ears). In this regard, we found that the histology score was significantly increased in the IMQ-control group compared to the sham group (P < 0.001, Figure 7(c)). In contrast, applying NOS (0.3, 1, 3, and 10% w/w) or Clo significantly reduced the histology score compared to the control group (P < 0.001 for all cases, Figure 7(c)).

4. Discussion

To the best of our knowledge, this is the first study that evaluated the protective effects of noscapine against the IMQ-induced mouse model. As a result, we revealed that noscapine concentration-dependently and significantly reduced the inflammation and psoriatic manifestation of IMQ by lowering the ear thickness and length and modulating the apoptosis (p53) and cell proliferative (Ki-67) factors.

Since the prevalence of pruritus in patients with psoriasis has been reported to be 60%-90%, and many patients with psoriasis consider pruritus to be the most annoying symptom [39, 40], this study also examined and showed significant results of the therapeutic effects of noscapine in the pruritus induction model by IMQ. In line with the present investigation, numerous studies have evaluated the prevalence of pruritus in patients with psoriasis. Still, in general, only a focused treatment with a molecular signaling survey can relieve the itching associated with psoriasis [41]. Psoriasis is a chronic inflammatory and autoimmune disease in which epithelial cell proliferation increases compared to normal skin [42]. The effects of methotrexate and clobetasol on cell proliferation [43] and the impact of these drugs on the immune system justify the effectiveness of these drugs in this disease that some patients might be sensitive to during long-term treatment [44]. Noscapine as an old drug has significant clinical effects, including antitussive properties and cell proliferation. Hence, we tried to evaluate the effectiveness of topical administration noscapine in the animal model of psoriasis. Following the results of this research, it is possible to continue studies in the human phase [45].

The results showed that the reduction in thickness and skin inflammation occurred from day seven in all concentrations of noscapine. In fact, we found that noscapine can reduce fibrosis and also inflammation in the ear by reducing the inflammatory mediators (TNF- α , TGF- β , IFN- γ , IL-6,





FIGURE 4: Number of scratching behavior in IMQ-induced psoriasis-like skin (a) and also H&E staining of cord sections revealed marked areas of necrosis with vacuolization of cells (b). The results are expressed as the mean \pm SD (n = 7 in each group). The results indicate significant changes compared to the negative control group (***P < 0.001).

IL-17, and IL-23p19), increasing IL-10 as an anti-inflammatory cytokine and modulating the apoptosis (p53) and cell proliferative (Ki-67) factors. The present study's findings were consistent with the results of other studies that indicated that topical administration of capsaicin significantly inhibited skin inflammation [46]. This reduction in thickness was not significant in the positive control group receiving the clobetasol from day six of treatment, indicating the superiority of the topical form of noscapine over the clobetasol application. Similar results were obtained in the therapeutic







FIGURE 5: Concentration of cytokines levels such as TNF- α (a), TGF- β (b), IFN- γ (c), IL-6 (d), IFN- γ /IL-10 (e), IL-10 (f), IL-17A (g), and IL-23p19 (h), respectively, showed in Figure 5(a)–5(h). The results are expressed as the mean ± SD (n = 7 in each group). The results indicate significant changes compared to the negative control group (***P < 0.001, **P < 0.01, and *P < 0.05).

effects of curcumin from day 6 of treatment in reducing inflammation and skin thickness in psoriasis-induced mice [47].

Numerous studies have reported the potent and significant antioxidant activity of noscapine [23, 48] in reducing the NF- κ B expression, which leads to a decrease in cytokine production by T-cells [23, 49, 50]. Currently, we demonstrated that noscapine considerably inhibited the proinflammatory mediator productions such as TNF- α or IFN γ . Our evidence suggests that noscapine has high antioxidant activity and substantially decrease the transcription of the TNF- α signaling indicator, resulting in a reduction in T-cell cytokine production. It was shown that TNF- α -mediated cytokines, TGF- β , IL-6, and IFN γ were considerably reduced in the noscapine treated groups than the positive control group. Our results align with previous studies that pointed out the anti-inflammatory properties of noscapine, primarily via modulating the NF- κ B signaling pathway in chemo-therapeutic agents [23, 51]. Accordingly, noscapine treatment could impress the release of pro-inflammatory cells cytokines due to environmental stress and stress-activated protein kinases [52]. In this regard, similar researches show that TLR-mediated TNF- α and nitric oxide (NO) production in human and murine macrophages was inhibited by



(b) FIGURE 6: Continued.





FIGURE 6: Hematoxylin and eosin (a) and trichrome staining (b) were presented for each sample. The pathologic changes in the ear pinna of various groups were included: acanthosis (c) parakeratosis (d) and thickening of the subepidermal layer (e) The data are expressed as the median \pm IQR, (n = 7 in each group). The results also indicate significant changes compared to the negative control group (***P < 0.001, **P < 0.01 and *P < 0.05).

brominated noscapine analogues (Br-nos and Red-Br-nos) with no indication of cellular damage [23]. Brominated noscapine analogs also reduced cytokine/chemokine (a non-TLR ligand)-induced sterile inflammation [23, 53].

It has been reported that IL-10 production has therapeutic benefits as common anti-psoriatic treatments on several cell types [54]. In this context, the present research results showed that treatment with all concentrations of noscapine except 0.3% NOS increases the level of IL-10. Furthermore, the current study results showed the effectiveness of a high concentration of noscapine (10%w/w) in regulating the expression of pro-inflammatory cytokines. Although definite mechanisms and signaling pathways in reducing these cytokines are indeterminate yet [23, 54], we believe that noscapine's antiproliferative and anti-inflammatory effects act through the suppression of $\text{TNF-}\alpha/\text{IFN}\gamma$, which results in more severe inflammation and keratinocyte proliferation. These findings are inconsistent with previous research that the anti-psoriatic effects of the Wannachawee recipe significantly inhibited the $\text{TNF-}\alpha$ and $\text{IFN}\gamma$.



(b) FIGURE 7: Continued.




FIGURE 7: Immunohistochemistry (IHC) staining for p53 protein (a) and Ki-67 protein (b) as specific antigen in an ear tissue based on antigen-antibody reaction by light microscopy. The histopathological score of examined tissues (c) is expressed as the median \pm IQR, (n = 7 in each group). The results also indicate significant changes compared to the negative control group (***P < 0.001, **P < 0.01 and *P < 0.05).




FIGURE 8: NOS alleviates IMQ-induced psoriasis-like skin lesions.

stimulated IL-17A, IL-22, and IL-23 secretion in HaCaT cells [26]. Although specific anti-inflammatory signaling pathways of noscapine in psoriasis induction are undefined, based on the current study results, we proposed that noscapine's antiproliferative and anti-inflammatory effect operates through the suppression of TNF- α /IFN γ /IL-23.

In conclusion, despite this investigation, it is well documented that noscapine can be considered as one of the therapeutic drugs in psoriasis disease and is widely evaluated in clinical trials studies. Figure 8 shows a graphical abstract of the procedure and possible protective mechanism of NOS against IMQ-induced psoriasis-like skin lesions.

Abbreviations

H and E:	Hematoxylin and eosin
IFN-γ:	Interferon-y
IL-10:	Interleukin 10
IL-17:	Interleukin 17
IL-23p19:	Interleukin 23p19
IL-6:	Interleukin 6
IMQ:	Imiquimod
NOS:	Noscapine
PASI:	Psoriasis area and severity index
PDCs:	Plasmacytoid dendritic cell
TGF-β:	Transforming growth factor- β
TLR:	Toll-like receptor
TNF- α :	Tumor necrosis factor-α.

Data Availability

The data used to support the findings of this study are available from the first author (F.N) upon reasonable request.

Ethical Approval

The study was conducted in compliance with ethical standards

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The presented results in this paper were elicited from the PhD student project and research protocol (990587), which was supported financially by the vice-chancellor for research, Mashhad University of Medical Sciences, Mashhad, Iran.

References

- V. R. Askari, V. B. Rahimi, R. Zargarani, R. Ghodsi, M. Boskabady, and M. H. Boskabady, "Anti-oxidant and antiinflammatory effects of auraptene on phytohemagglutinin (PHA)-induced inflammation in human lymphocytes," *Pharmacological Reports*, vol. 73, no. 1, pp. 154–162, 2021.
- [2] V. R. Askari, V. Baradaran Rahimi, S. A. Tabatabaee, and R. Shafiee-Nick, "Combination of imipramine, a sphingomyelinase inhibitor, and β-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE)," *International Immunopharmacology*, vol. 77, Article ID 105923, 2019.
- [3] V. Baradaran Rahimi, V. R. Askari, and S. H. Mousavi, "Ellagic acid dose and time-dependently abrogates d-galactose-induced animal model of aging: investigating the role of PPAR-*y*," *Life Sciences*, vol. 232, Article ID 116595, 2019.
- [4] V. Baradaran Rahim, M. T. Khammar, H. Rakhshandeh, A. Samzadeh-Kermani, A. Hosseini, and V. R. Askari, "Crocin protects cardiomyocytes against LPS-Induced inflammation," *Pharmacological Reports*, vol. 71, no. 6, pp. 1228–1234, 2019.
- [5] M. Boskabady, M. R. Khazdair, R. Bargi et al., "Thymoquinone ameliorates lung inflammation and pathological changes

observed in lipopolysaccharide-induced lung injury," *Evidence-Based Complementary and Alternative Medicine*, vol. 2021, Article ID 6681729, 10 pages, 2021.

- [6] M. Sticherling, "Psoriasis and autoimmunity," Autoimmunity Reviews, vol. 15, no. 12, pp. 1167–1170, 2016.
- [7] T. Henseler and E. Christophers, "Disease concomitance in psoriasis," *Journal of the American Academy of Dermatology*, vol. 32, no. 6, pp. 982–986, 1995.
- [8] R. Parisi, D. P. Symmons, C. E. Griffiths, and D. M. Ashcroft, "Global epidemiology of psoriasis: a systematic review of incidence and prevalence," *Journal of Investigative Dermatology*, vol. 133, no. 2, pp. 377–385, 2013.
- [9] J. E. Gudjonsson and J. T. Elder, "Psoriasis: epidemiology," *Clinics in Dermatology*, vol. 25, no. 6, pp. 535–546, 2007.
- [10] N. D. Loft, L. Skov, M. K. Rasmussen et al., "Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis," *PLoS One*, vol. 13, no. 2, Article ID e0192010, 2018.
- [11] A. L. Neimann, S. B. Porter, and J. M. Gelfand, "The epidemiology of psoriasis," *Expert Review of Dermatology*, vol. 1, no. 1, pp. 63–75, 2006.
- [12] F. Benhadou, D. Mintoff, and V. Del Marmol, "Psoriasis: keratinocytes or immune cells-which is the trigger?" *Dermatology*, vol. 235, no. 2, pp. 91–100, 2019.
- [13] L. Flatz and C. Conrad, "Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy," *Psoriasis: Targets and Therapy*, vol. 3, pp. 1–10, 2013.
- [14] Y. Deng, C. Chang, and Q. Lu, "The inflammatory response in psoriasis: a comprehensive review," *Clinical Reviews in Allergy* & *Immunology*, vol. 50, no. 3, pp. 377–389, 2016.
- [15] A. Ueyama, M. Yamamoto, K. Tsujii et al., "Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod," *The Journal of Dermatology*, vol. 41, no. 2, pp. 135–143, 2014.
- [16] A. El Tawdy, I. M. Amin, R. Abdel Hay, A. S. Hassan, Z. S. Gad, and L. A. Rashed, "Toll-like receptor (TLR) 7 expression in mycosis fungoides and psoriasis: a case-control study," *Clinical and Experimental Dermatology*, vol. 42, no. 2, pp. 172–177, 2017.
- [17] R. Rashmi, K. S. J. Rao, and K. H. Basavaraj, "A comprehensive review of biomarkers in psoriasis," *Clinical and Experimental Dermatology*, vol. 34, no. 6, pp. 658–663, 2009.
- [18] A. K. Gupta, M. Browne, and R. Bluhm, "Imiquimod: a review," *Journal of Cutaneous Medicine and Surgery*, vol. 6, no. 6, pp. 554–560, 2002.
- [19] M. Schön and M. Schön, "Imiquimod: mode of action," British Journal of Dermatology, vol. 157, pp. 8–13, 2007.
- [20] S. Shen, T. O'Brien, L. M. Yap, H. M. Prince, and C. J. McCormack, "The use of methotrexate in dermatology: a review," *Australasian Journal of Dermatology*, vol. 53, no. 1, pp. 1–18, 2012.
- [21] J. Seetharaman and S. Rajan, "Crystal and molecular structure of noscapine 1," Zeitschrift für Kristallographie-Crystalline Materials, vol. 210, no. 2, pp. 111–113, 1995.
- [22] F. Nourbakhsh and V. R. Askari, "Biological and pharmacological activities of noscapine: focusing on its receptors and mechanisms," *BioFactors*, vol. 47, no. 6, pp. 975–991, 2021.
- [23] P. Rahmanian-Devin, V. Baradaran Rahimi, M. R. Jaafari, S. Golmohammadzadeh, Z. Sanei-far, and V. R. Askari, "Noscapine, an emerging medication for different diseases: a mechanistic review," *Evidence-based Complementary and Alternative Medicine*, vol. 2021, Article ID 8402517, 16 pages, 2021.

- [24] X. Chen, T.-T. T. Dang, and P. J. Facchini, "Noscapine comes of age," *Phytochemistry*, vol. 111, pp. 7–13, 2015.
- [25] H. Singh, P. Singh, K. Kumari, A. Chandra, S. K Dass, and R. Chandra, "A review on noscapine, and its impact on heme metabolism," *Current Drug Metabolism*, vol. 14, no. 3, pp. 351–360, 2013.
- [26] M. Na Takuathung, A. Wongnoppavich, A. Panthong et al., "Antipsoriatic effects of wannachawee recipe on imiquimodinduced psoriasis-like dermatitis in BALB/c mice," *Evidence-Based Complementary and Alternative Medicine*, vol. 2018, Article ID 7931031, 13 pages, 2018.
- [27] K. Sakai, K. M. Sanders, M. R. Youssef et al., "Mouse model of imiquimod-induced psoriatic itch," *Pain*, vol. 157, no. 11, pp. 2536–2543, 2016.
- [28] A. Jaafari, V. Baradaran Rahimi, N. Vahdati-Mashhadian et al., "Evaluation of the therapeutic effects of the hydroethanolic extract of *Portulaca oleracea* on surgical-induced peritoneal adhesion," *Mediators of Inflammation*, vol. 2021, Article ID 8437753, 18 pages, 2021.
- [29] A. T. Feldman and D. Wolfe, "Tissue processing and hematoxylin and eosin staining," *Histopathology*, pp. 31–43, Springer, Berlin, Germany, 2014.
- [30] N. C. Foot, "The masson trichrome staining methods in routine laboratory use," *Stain Technology*, vol. 8, no. 3, pp. 101–110, 1933.
- [31] S. Y. Park, D. Gupta, R. Hurwich, C. H. Kim, and R. Dziarski, "Peptidoglycan recognition protein Pglyrp2 protects mice from psoriasis-like skin inflammation by promoting regulatory T cells and limiting Th17 responses," *The Journal of Immunology*, vol. 187, no. 11, pp. 5813–5823, 2011.
- [32] F. M. Hofman and C. R. Taylor, "Immunohistochemistry," *Current Protocols in Immunology*, vol. 103, no. 1, p. 21, 2013.
- [33] A.-A. Grosset, K. Loayza-Vega, É. Adam-Granger et al., "Hematoxylin and eosin counterstaining protocol for immunohistochemistry interpretation and diagnosis," *Applied Immunohistochemistry & Molecular Morphology*, vol. 27, no. 7, pp. 558–563, 2019.
- [34] M. M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.
- [35] V. Baradaran Rahimi, A. Rajabian, H. Rajabi et al., "The effects of hydro-ethanolic extract of Capparis spinosa (C. spinosa) on lipopolysaccharide (LPS)-induced inflammation and cognitive impairment: evidence from in vivo and in vitro studies," *Journal of Ethnopharmacology*, vol. 256, Article ID 112706, 2020.
- [36] M. J. Curtis, R. A. Bond, D. Spina et al., "Experimental design and analysis and their reporting: new guidance for publication in BJP," *British Journal of Pharmacology*, vol. 172, no. 14, pp. 3461–3471, 2015.
- [37] C. H. George, S. C. Stanford, S. Alexander et al., "Updating the guidelines for data transparency in the British Journal of Pharmacology - data sharing and the use of scatter plots instead of bar charts," *British Journal of Pharmacology*, vol. 174, no. 17, pp. 2801–2804, 2017.
- [38] S. P. H. Alexander, R. E. Roberts, B. R. S. Broughton et al., "Goals and practicalities of immunoblotting and immunohistochemistry: a guide for submission to the British Journal of Pharmacology," *British Journal of Pharmacology*, vol. 175, no. 3, pp. 407–411, 2018.
- [39] A. G. Bahali, N. Onsun, O. Su et al., "The relationship between pruritus and clinical variables in patients with psoriasis,"

Anais Brasileiros de Dermatologia, vol. 92, no. 4, pp. 470–473, 2017.

- [40] G. Yosipovitch, A. Goon, J. Wee, Y. Chan, and C. Goh, "The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis," *British Journal of Dermatology*, vol. 143, no. 5, pp. 969–973, 2000.
- [41] S. Kahremany, L. Hofmann, M. Harari, A. Gruzman, and G. Cohen, "Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives," *Pharmacological Reports*, vol. 73, no. 2, pp. 443–453, 2021.
- [42] H. Valdimarsson, R. H. Thorleifsdottir, S. L. Sigurdardottir, J. E. Gudjonsson, and A. Johnston, "Psoriasis-as an autoimmune disease caused by molecular mimicry," *Trends in Immunology*, vol. 30, no. 10, pp. 494–501, 2009.
- [43] N. Vincent, D. D. Ramya, and H. B. Vedha, "Progress in psoriasis therapy via novel drug delivery systems," *Dermatology Reports*, vol. 6, no. 1, 2014.
- [44] P. Zwicky, S. Unger, and B. Becher, "Targeting interleukin-17 in chronic inflammatory disease: a clinical perspective," *Journal of Experimental Medicine*, vol. 217, no. 1, 2020.
- [45] M. Mahmoudian and P. Rahimi-Moghaddam, "The anticancer activity of noscapine: a review," *Recent Patents on Anti-Cancer Drug Discovery*, vol. 4, no. 1, pp. 92–97, 2009.
- [46] P. R. Desai, S. Marepally, A. R. Patel, C. Voshavar, A. Chaudhuri, and M. Singh, "Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo," *Journal of Controlled Release*, vol. 170, no. 1, pp. 51–63, 2013.
- [47] J. Sun, Y. Zhao, and J. Hu, "Curcumin inhibits imiquimodinduced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice," *PLoS One*, vol. 8, no. 6, Article ID e67078, 2013.
- [48] A. Shaghaghi, A. Alirezalu, E. Nazarianpour, A. Sonboli, and S. Nejad-Ebrahimi, "Opioid alkaloids profiling and anti-oxidant capacity of Papaver species from Iran," *Industrial Crops* and Products, vol. 142, Article ID 111870, 2019.
- [49] B. Sung, K. S. Ahn, and B. B. Aggarwal, "Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-κB signaling pathway," *Cancer Research*, vol. 70, no. 8, pp. 3259–3268, 2010.
- [50] S. A. Ebrahimi, "Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2," *Drug Development Research*, vol. 81, no. 7, pp. 765–767, 2020.
- [51] V. Tomar, S. Kukreti, S. Prakash, J. Madan, and R. Chandra, "Noscapine and its analogs as chemotherapeutic agent: current updates," *Current Topics in Medicinal Chemistry*, vol. 17, no. 2, pp. 174–188, 2016.
- [52] A. T. Funding, C. Johansen, K. Kragballe et al., "Mitogen-and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines," *Journal of Investigative Dermatology*, vol. 126, no. 8, pp. 1784–1791, 2006.
- [53] S. Zughaier, P. Karna, D. Stephens, and R. Aneja, "Potent antiinflammatory activity of novel microtubule-modulating brominated noscapine analogs," *PLoS One*, vol. 5, no. 2, Article ID e9165, 2010.
- [54] K. Kingo, S. Koks, H. Silm, and E. Vasar, "IL-10 promoter polymorphisms influence disease severity and course in psoriasis," *Genes and Immunity*, vol. 4, no. 6, pp. 455–457, 2003.